Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03009396 · ClinicalTrials.gov registry record · Phase 3
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
A Phase 3 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT03009396 is a Phase 3 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 54 participants.
The verdict
NCT03009396, a Phase 3 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
An open label extension to the RHB-104-01 Study.
Interventions
- DRUG RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-03-18 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03009396
The ClinicalTrials.gov registry entry for NCT03009396 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) is the first listed.
NCT03009396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03009396 about?
NCT03009396 is a clinical study titled "Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease". An open label extension to the RHB-104-01 Study.
What is the current status of trial NCT03009396?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2017-03-18. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT03009396?
The interventions under investigation include: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) (DRUG).
Who is sponsoring clinical trial NCT03009396?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.